Abstract
Diastolic dysfunction encompasses both those who are asymptomatic and those who have heart failure symptoms. Preclinical diastolic dysfunction (PDD), defined as diastolic dysfunction with preserved ejection fraction (EF) without the presence of heart failure symptoms, is prevalent and may progress to heart failure with preserved EF (HFpEF). While the causative factors of HFpEF are multifactorial, targeting PDD and its associated comorbidities prior to development of symptoms can reduce development of heart failure. Diabetes, coronary artery disease, hypertension, and renal dysfunction are targets of treatment in those with diastolic dysfunction that may decrease the risk of heart failure development. This review will focus on PDD, its epidemiology, pathophysiology, comorbid conditions, and management that may prevent development of heart failure.
Original language | English (US) |
---|---|
Article number | 40 |
Journal | Current Cardiovascular Risk Reports |
Volume | 9 |
Issue number | 8 |
DOIs | |
State | Published - Aug 25 2015 |
Fingerprint
Keywords
- Diastolic dysfunction
- Echocardiography
- Heart failure epidemiology
- Heart failure treatment
- Heart failure with preserved ejection fraction
- Preclinical diastolic dysfunction
ASJC Scopus subject areas
- Pharmacology (medical)
- Pharmacology
Cite this
Targeting Preclinical Diastolic Dysfunction to Prevent Heart Failure : Contemporary Insights. / Wan, Siu Hin; Chen, Horng Haur.
In: Current Cardiovascular Risk Reports, Vol. 9, No. 8, 40, 25.08.2015.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Targeting Preclinical Diastolic Dysfunction to Prevent Heart Failure
T2 - Contemporary Insights
AU - Wan, Siu Hin
AU - Chen, Horng Haur
PY - 2015/8/25
Y1 - 2015/8/25
N2 - Diastolic dysfunction encompasses both those who are asymptomatic and those who have heart failure symptoms. Preclinical diastolic dysfunction (PDD), defined as diastolic dysfunction with preserved ejection fraction (EF) without the presence of heart failure symptoms, is prevalent and may progress to heart failure with preserved EF (HFpEF). While the causative factors of HFpEF are multifactorial, targeting PDD and its associated comorbidities prior to development of symptoms can reduce development of heart failure. Diabetes, coronary artery disease, hypertension, and renal dysfunction are targets of treatment in those with diastolic dysfunction that may decrease the risk of heart failure development. This review will focus on PDD, its epidemiology, pathophysiology, comorbid conditions, and management that may prevent development of heart failure.
AB - Diastolic dysfunction encompasses both those who are asymptomatic and those who have heart failure symptoms. Preclinical diastolic dysfunction (PDD), defined as diastolic dysfunction with preserved ejection fraction (EF) without the presence of heart failure symptoms, is prevalent and may progress to heart failure with preserved EF (HFpEF). While the causative factors of HFpEF are multifactorial, targeting PDD and its associated comorbidities prior to development of symptoms can reduce development of heart failure. Diabetes, coronary artery disease, hypertension, and renal dysfunction are targets of treatment in those with diastolic dysfunction that may decrease the risk of heart failure development. This review will focus on PDD, its epidemiology, pathophysiology, comorbid conditions, and management that may prevent development of heart failure.
KW - Diastolic dysfunction
KW - Echocardiography
KW - Heart failure epidemiology
KW - Heart failure treatment
KW - Heart failure with preserved ejection fraction
KW - Preclinical diastolic dysfunction
UR - http://www.scopus.com/inward/record.url?scp=84934967513&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84934967513&partnerID=8YFLogxK
U2 - 10.1007/s12170-015-0466-1
DO - 10.1007/s12170-015-0466-1
M3 - Article
AN - SCOPUS:84934967513
VL - 9
JO - Current Cardiovascular Risk Reports
JF - Current Cardiovascular Risk Reports
SN - 1932-9520
IS - 8
M1 - 40
ER -